

VACCINE AGAINST INCLUSION BODY HEPATITIS

Opportunity

Researchers at the University of Saskatchewan have produced a novel vaccine against inclusion body hepatitis in broiler chickens.

No live vaccine against a wide range of adenoviral strains is currently available.

Background

Inclusion body hepatitis is the most prevalent infectious disease affecting the poultry industry in Canada (*Gomis S. et al, 2006*) and is an emerging problem worldwide. In Canada, the annual direct costs associated with this disease are estimated at over \$10 million.

Inclusion body hepatitis is caused by fowl adenovirus (FAdV) and lasts 7-14 days with a mortality rate of 5-30%. FAdV infection affects chickens from 10 days to 6 weeks old.

Benefits to Our Solution

- Superior protection of parents and progeny against a range of adenoviral strains, including homologous and heterologous strains,
- Composed of FAdV-2, FAdV-7, FAdV-8a/8b or FAdV-11 serotype strains,
- Efficient and easy delivery routes, including “water supplementation”.

Patent status

US patent application no. 12/969,444.

CA patent application no. 2,725,435.

Publications

1. Gomis S, Goodhope R, Ojkic D, and Wilson P. Inclusion Body Hepatitis as a Primary Disease in Broilers in Saskatchewan. *Canada Avian Diseases*, 50(4):550-555 (2006).
2. Ojkic D, Martin E, Swinton J, Vaillancourt JP, Boulianne M, and Gomis S. Genotyping of Canadian isolates of fowl adenoviruses. *Avian Pathol.* 37(1): 95-100 (2008b).

Inventor: Dr. Susantha Gomis

Reference: 09-009

For more information:
Innovation Enterprise
Life Sciences Portfolio Manager

ie.contact@usask.ca
+1 306 966 1465

250 – 15 Innovation
Blvd Saskatoon, SK
S7N 2X8 Canada



UNIVERSITY OF SASKATCHEWAN

Innovation Enterprise

OFFICE OF THE VICE-PRESIDENT RESEARCH
RESEARCH.USASK.CA/IE